Calprotectin and Platelet Aggregation in Patients with Stable Coronary Artery Disease

Recent studies suggest that the inflammation-associated protein calprotectin may be implicated in the pathogenesis of coronary artery disease (CAD). However, the impact of calprotectin levels on platelet aggregation in CAD patients has never been investigated.We investigated the association between calprotectin levels and platelet aggregation in stable, high-risk CAD patients receiving aspirin as mono antiplatelet therapy. Furthermore, we aimed to investigate independent clinical and laboratory determinants of calprotectin levels., both measured by ELISA. levels in all patients (median [25%;75%]: 1.07 [0.52;1.87] ng/mL). in high-risk, stable CAD patients treated with aspirin